Disease Diagnosis Revolution: Introducing the Liquid Biopsy Report for Advanced Illness Detection and Monitoring
The much-anticipated 2021 Liquid Biopsy Intelligence Report is set to be launched this year, offering a wealth of insights and advancements in the field from leading experts. This report, contributed by 17 esteemed professionals, including Hong Chen, Associate Professor of Biomedical Engineering and Neurosurgery, Aadel Chaudhuri, Assistant Professor of Radiation Oncology, and Catherine Alix-Panabières, Director of the Laboratory of Rare Circulating Human Cells, is an invaluable resource for the liquid biopsy research community.
The report provides a comprehensive overview of liquid biopsy technologies, focusing on biomarker types, clinical applications in various cancers, technological improvements in detection methods, market dynamics, and ongoing challenges and prospects in the field.
One of the key areas covered is the use of liquid biopsy as a less invasive method for detecting cancers like liver cancer, breast cancer, and colorectal cancer. The report emphasises the importance of early detection, diagnosis, prognosis, treatment monitoring, and resistance evaluation. It also reviews workflow optimization for maximising sensitivity in next-generation sequencing (NGS) of cell-free DNA (cfDNA) and discusses innovations such as RNA-based liquid biopsy tests that improve early-stage cancer detection accuracy.
The report also delves into the potential of liquid biopsy in diagnosing neurological disorders faster. While limitations in diagnosing neurological conditions are discussed, the report highlights the transformative potential of liquid biopsy in diagnostics and personalised medicine for complex diseases.
In addition, the 2021 Liquid Biopsy Intelligence Report includes a helpful guide to liquid biopsy biomarker analysis, featuring the latest products, equipment, and commercially available assays. It also offers updates and results from major clinical trials and programs, including the NHS-Galleri trial.
Chapter 6 explores the current landscape of liquid biopsy clinical trials and the limitations that need to be addressed. The final chapter (Chapter 7) provides insights into future advancements that will drive liquid biopsy forward. Throughout the report, exclusive interviews and insights from the contributors offer valuable perspectives on the current state and future of liquid biopsy.
In summary, the 2021 Liquid Biopsy Intelligence Report is a comprehensive guide that provides detailed analysis of recent advances and clinical relevance of liquid biopsy technologies. It offers a valuable resource for researchers, clinicians, and anyone interested in the future of diagnostics and personalised medicine.
- The report highlights the potential of liquid biopsy in diagnosing not only various cancers such as liver, breast, and colorectal cancers, but also neurological disorders faster.
- It discusses the importance of early detection, diagnosis, prognosis, treatment monitoring, and resistance evaluation in cancers using liquid biopsy technologies.
- The report reviews workflow optimization for maximizing sensitivity in next-generation sequencing (NGS) of cell-free DNA (cfDNA) and introduces innovations such as RNA-based liquid biopsy tests for enhanced early-stage cancer detection accuracy.
- In addition to the details about cancers, the 2021 Liquid Biopsy Intelligence Report includes a guide to liquid biopsy biomarker analysis, featuring the latest products, equipment, and commercially available assays.
- The report offers updates and results from major clinical trials and programs like the NHS-Galleri trial, providing insights into the current landscape of liquid biopsy clinical trials.
- The final chapter of the report, Chapter 7, provides insights into future advancements that will drive liquid biopsy forward in the field of science, medical-conditions, health-and-wellness, therapy, and personalized medicine.
